Reviewing Forte Biosciences (NASDAQ:FBRX) and Pasithea Therapeutics (NASDAQ:KTTA)

Forte Biosciences (NASDAQ:FBRX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Forte Biosciences and Pasithea Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1	0	3	0	2.50
Pasithea Therapeutics	1	1	1	0	2.00

Forte Biosciences presently has a consensus target price of $67.00, indicating a potential upside of 161.92%. Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 289.66%. Given Pasithea Therapeutics’ higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Forte Biosciences.

Profitability

This table compares Forte Biosciences and Pasithea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-75.64%	-65.94%
Pasithea Therapeutics	N/A	-151.82%	-135.28%

Insider & Institutional Ownership

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Forte Biosciences and Pasithea Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$35.48 million	($4.77)	-5.36
Pasithea Therapeutics	N/A	N/A	-$13.90 million	($3.57)	-0.22

Forte Biosciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Forte Biosciences has a beta of 3.2, meaning that its stock price is 220% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Summary

Forte Biosciences beats Pasithea Therapeutics on 7 of the 11 factors compared between the two stocks.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.